PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001

Item
http://www.wikidata.org/entity/Q34028766
PI3K mutations in breast cancer: prognostic and therapeutic implicationsClinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses.Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancerPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistancePerifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancerPrevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.mTOR pathway in colorectal cancer: an update.Oncogene mutational profile in nasopharyngeal carcinoma.A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer.Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.Determination of the Relative Efficacy of Eicosapentaenoic Acid and Docosahexaenoic Acid for Anti-Cancer Effects in Human Breast Cancer Models.Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.Braking self-cannibalism in cancer.
P2860

PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001

Item
http://www.wikidata.org/entity/Q34028766
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@ast
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@en
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@nl
type
label
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@ast
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@en
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@nl
prefLabel
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@ast
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@en
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932